Communicators

Pluristem Therapeutics to Sponsor the World Conference on Regenerative Medicine

NEW YORK - Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that it will be sponsoring the World Conference on Regenerative Medicine to be held on October 29-31, 2009 in Leipzig, Germany. The conference, which will be organized by the Fraunhofer Institute for Cell Therapy and Immunology, will provide a platform for the exchange of information on stem cells, tissue engineering, technology development such as bioreactors, immunology signaling and regulatory topics.

“Pluristem is honored to sponsor the World Conference of Regenerative Medicine”, stated Zami Aberman, Chairman, President and CEO of Pluristem. “This conference presents the current science on the threshold of cell therapy, and we at Pluristem believe that cell therapy will give patients a better chance”, he added.

Prof. Dr. Frank Emmrich, Director of the Institute for Clinical Immunology and Transfusion Medicine, University of Leipzig, Germany stated, “We are pleased that Pluristem continues to sponsor the World Conference on Regenerative Medicine. Pluristem’s involvement reflects its continuous commitment to the field of bio-therapy as well as the Company’s acknowledgment of the significance of the German scientific institutions in Leipzig.”

http://www.wcrm-leipzig.com/index.php

About Fraunhofer Institute for Immunology and Cell Therapy

The objective of the Fraunhofer Institute for Immunology and Cell Therapy (IZI) is to find solutions to specific problems at the interfaces between medicine, life sciences and engineering for partners active in medicine-related industries and businesses. The Institute’s core competencies are found in regenerative medicine, or more precisely in cell-therapeutic methods of regenerating non-functioning tissue and organs through to biological substitution with tissue cultivated in vitro (tissue engineering). In order for the living organism to accept these tissues without difficulty, it is necessary to study cellular and immunological defense and control mechanisms and take these into account during the process product development. These core competencies entail a multiplicity of tasks to be solved by new products and processes.

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.

These placental adherent stromal cells (ASCs) are expanded in the Company's proprietary PluriXTM 3D bioreactor, which imitates the natural 3D microenvironment of these cells and does not require supplemental growth factors or other exogenous materials. Pluristem believes that the resultant PLX (PLacental eXpanded) cells’ efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and possess immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.

Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company's products in development also include PLX-IBD, targeting Inflammatory Bowel Disease (IBD); PLX-MS, targeting Multiple Sclerosis; PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; and PLX-STROKE, targeting ischemic stroke.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.

See our product animation on YouTube: Animation

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we say that we will present our clinical trial’s progress, as well as the Company's future business plans, to the investment community at the Stuttgart Equity Forum, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.

Contact:

Pluristem Therapeutics Inc.
William Prather RPh, MD
Sr. VP Corporate Development
+1-303-883-4954
William.PratherMD@pluristem.com



NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=US72940R1023

Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.